Many stayed home, assumed it was COVID, and arrived with advanced lesions.
When a pandemic consumes a nation's health infrastructure, the diseases it displaces do not disappear — they deepen. Peru's tuberculosis detection system, which had spent years painstakingly closing in on one of the hemisphere's heaviest disease burdens, was effectively suspended during COVID-19, sending case identification rates back to levels unseen in a decade. The human cost of that interruption is now visible in advanced lung damage, rising mortality, and a backlog of suffering concentrated among the country's most vulnerable — the malnourished, the crowded, the poor — in a nation that already leads the Americas in drug-resistant TB.
- Peru's TB detection rate collapsed from 89% to 66% in a single year — the sharpest regression in a decade — as health workers were pulled wholesale into COVID-19 response, leaving the slow, methodical machinery of tuberculosis surveillance to grind to a halt.
- Patients who stayed home assuming their coughs were COVID arrived at clinics months later with advanced lung lesions, meaning the pandemic didn't just delay diagnosis — it allowed the disease to cause far greater harm before anyone intervened.
- The burden falls hardest on the margins: Loreto's TB positivity rate is more than double the national average, Cajamarca's death rates suggest patients are found too late, and Lima and Callao together carry 60% of all cases amid crowded housing and chronic poverty.
- The government is deploying 18 backpack-portable digital X-ray units with AI screening and rapid molecular tests capable of diagnosing drug-resistant strains within hours — compressing what once took days into a single clinical encounter.
- Epidemiologists warn that technology cannot outpace the social conditions driving transmission — malnutrition, overcrowding, and economic precarity — and it remains uncertain whether a health system still recovering from the pandemic can act swiftly enough on what it now finds.
Peru's tuberculosis detection system lost a decade of progress in a single year. By mid-2022, the Ministry of Health had confirmed what public health officials feared: case identification had fallen from 89.1 percent in 2019 to just 66.4 percent in 2020 — a collapse with no recent precedent in the country's epidemiological records.
The mechanism was blunt. When COVID-19 arrived, community health workers stopped searching for persistent coughs. Lab technicians were reassigned. The constant, methodical outreach that TB detection depends on simply stopped. Program director Julia Ríos described the consequence: people stayed home, assumed their symptoms were COVID, and by the time they sought care, their infections had progressed to visible lung damage. The disease had been given time to burrow deeper.
Detection recovered modestly to 71.5 percent in 2021, but Peru's underlying burden remained severe. The country ranks second globally in TB case volume and first in the Americas for drug-resistant tuberculosis. Twelve regions carry very high or high risk. Loreto's positivity rate of 6 percent is more than double the national average, while Lima and Callao account for 60 percent of all cases — a concentration shaped by crowded housing, malnutrition, and poor ventilation. In Cajamarca, unusually high death rates among diagnosed patients point to late detection and inadequate support.
The government has begun responding. Eighteen portable digital X-ray units, small enough to carry into public squares, are being distributed to prioritized regions. Combined with rapid molecular tests that can identify drug-resistant strains within hours, the full diagnostic chain — from screening to treatment decision — can now be completed in a single day, at no cost to the patient.
Yet epidemiologist César Ugarte cautions that tuberculosis is fundamentally a social disease. A patient who is malnourished, living in a windowless room, and unable to miss work cannot be healed by medicine alone. The Ministry's forthcoming treatment guidelines will lower the threshold for testing — a cough lasting ten days will now be enough to warrant investigation — a modest but meaningful shift for a system still struggling to find its footing after the pandemic's long disruption.
Peru's tuberculosis detection system has collapsed backward by a full decade, undone by the COVID-19 pandemic. The Ministry of Health confirmed in mid-2022 what public health officials had been watching with growing alarm: the country's ability to find and diagnose TB cases had fallen to levels not seen since the early 2010s. In 2019, Peru identified 89.1 percent of its estimated tuberculosis cases—nearly 33,000 people caught and treated before the disease advanced. By 2020, that number had plummeted to 66.4 percent, a drop so severe it had no recent precedent in the country's epidemiological records.
The cause was straightforward and devastating. When COVID-19 struck, Peru's health workers—already stretched thin—pivoted almost entirely to pandemic response. Community health workers who had spent their days searching for people with persistent coughs stopped doing so. Laboratory technicians and radiologists were reassigned. The machinery of TB detection, which depends on constant, methodical outreach and testing, simply ground to a halt. Julia Ríos, who directs Peru's tuberculosis prevention and control program, explained the human consequence plainly: people stayed home, assumed their symptoms were COVID, and by the time they finally sought care, their infections had progressed to advanced stages with visible lung damage. The disease had been given time to burrow deeper.
By 2021, detection had recovered slightly to 71.5 percent of expected cases. Through April 2022, Peru had identified 8,892 TB cases—still far below what epidemiologists estimated the true burden to be. The numbers matter because tuberculosis remains the world's deadliest infectious disease after COVID-19, and Peru carries an outsized share of the global burden. The country ranks second globally in TB case volume, behind only Haiti. When it comes to drug-resistant tuberculosis—the most dangerous and difficult-to-treat form—Peru leads all of the Americas.
The disease is not evenly distributed across the country. Twelve regions face either very high or high risk. The eastern jungle regions of Ucayali, Madre de Dios, and Loreto show the most alarming patterns. In Loreto, the rate of positive TB tests reaches 6 percent, more than double the national average of 2.5 percent, indicating intense community transmission. Lima and Callao together account for 60 percent of all cases, a concentration that reflects both population density and the social conditions that allow tuberculosis to spread: crowded housing, malnutrition, poor ventilation. Yet Cajamarca, a highland region with fewer total cases, shows unusually high death rates among those diagnosed, suggesting late detection and inadequate treatment support.
The Ministry of Health has begun deploying countermeasures. Eighteen digital X-ray units—portable enough to fit in backpacks and move between public squares and community spaces—are being distributed to prioritized regions. These machines can capture images and use artificial intelligence to flag probable TB cases, which are then confirmed through rapid molecular tests. The entire diagnostic chain, from initial screening to treatment decision, can now happen in a single day, and both treatment and preventive therapy are free. The government is also rolling out the Xpert molecular test, which can identify not just tuberculosis but also drug-resistant strains within hours.
But technology alone cannot close the gap. César Ugarte, an epidemiologist specializing in TB, argues that the disease is fundamentally a social problem. A patient who is malnourished, living in a crowded room with no windows, and unable to afford to miss work cannot be cured by medicine alone. The most complicated cases, he noted, almost always involve people living in poverty. The Ministry of Health is preparing an updated treatment guideline, expected by the end of June 2022, that will lower the threshold for suspicion—a persistent cough lasting ten days or more will now be enough to warrant testing, without requiring fever or weight loss. It is a small change, but in a system struggling to find cases, it may help pull more people into diagnosis before their disease becomes severe. What remains unclear is whether Peru's health system, still recovering from the pandemic's demands, has the capacity to act on what it finds.
Citas Notables
The pandemic was very aggressive. A decade ago Peru and the world didn't see this kind of drop in TB detection, and people arrived with much more advanced lung damage.— Julia Ríos, director of Peru's tuberculosis prevention and control program
TB is a social disease that reflects inequality. Treatment alone means nothing if a person is malnourished, living in crowded conditions with no ventilation, and has no social support.— César Ugarte, epidemiologist specializing in tuberculosis
La Conversación del Hearth Otra perspectiva de la historia
Why did TB detection fall so dramatically when COVID arrived? Couldn't health workers do both?
In theory, yes. In practice, Peru's health system was already stretched. When COVID hit, it became an all-hands emergency. The workers who did community outreach—visiting homes, screening people with coughs—were pulled to hospitals and testing sites. Some got sick themselves. Some died. The machinery of TB detection requires constant, patient work in communities. You can't pause that and restart it cleanly.
So people with TB just... went undiagnosed for months or years?
Many did. They stayed home thinking they had COVID. By the time they came to a clinic, their lungs were already damaged. That's why Ríos mentioned patients arriving with advanced lesions. The disease had time to progress.
Peru is second in the world for TB cases. Why is that?
Social determinants. Crowding, malnutrition, poor housing ventilation. Lima and Callao have 60 percent of cases because they're dense cities with poverty. But Loreto in the jungle is even worse proportionally—6 percent of tests come back positive there, versus 2.5 nationally. That means the virus is spreading fast through communities.
What about drug-resistant TB? That sounds terrifying.
It is. Peru has the highest rate of drug-resistant TB in the Americas. These strains don't respond to standard antibiotics. They require longer, harsher treatment. If you can't detect them early, they become nearly impossible to treat.
The digital X-ray units sound promising. Will those fix the problem?
They help. A portable machine that can screen people and confirm cases in one day is genuinely useful. But an epidemiologist I read said the real issue is social. You can diagnose someone perfectly, but if they're hungry and living in a room with ten other people, medicine alone won't cure them. You need money for food, housing support, social care.
So what happens next?
The government is updating treatment guidelines and distributing more diagnostic equipment. But whether that translates to actual detection and cure depends on whether the health system has recovered enough to do the work. That's still an open question.